An extraordinarily potent HGF/Met signaling enhancer — claimed to be 7 orders of magnitude more potent than BDNF.
Dihexa is a nonapeptide (9-amino acid derivative) developed by Joseph Harding and colleagues at Washington State University. It is derived from angiotensin IV and acts by potentiating HGF (hepatocyte growth factor) signaling through the Met receptor, which promotes synaptogenesis — the formation of new synaptic connections in the brain.
The remarkable aspect of Dihexa is its claimed potency: in animal studies, it was reported to be 10 million times (7 orders of magnitude) more potent than BDNF at promoting synaptogenesis. This extraordinary potency claim, if validated in humans, would make it one of the most powerful cognitive enhancers studied. However, this is preclinical data only.
Dihexa is not a conventional peptide — it is a chemically modified peptide analog with unusual stability and oral/transdermal bioavailability. This distinguishes it from most therapeutic peptides that require injection. However, it remains entirely in the research phase with no human clinical trials completed.
Animal studies in rats demonstrated dramatic improvements in spatial memory tasks, reversal of cognitive deficits in Alzheimer's-like models, and promotion of synaptic density. The HGF/Met pathway is well-established in neuroscience as important for synaptic plasticity.
No human clinical trials have been completed. The translation from rodent cognitive enhancement to human benefit is uncertain and historically has been difficult with many similar compounds. The extraordinary potency claims have not been independently validated in humans.
📚 Key Reference: PMID: 23195548 (Dihexa synaptogenesis study)
No human clinical trial safety data. Rodent safety profile appears acceptable at studied doses. Concerns include unknown off-target effects at such high potency. HGF/Met signaling is involved in cancer pathways — potential oncological concerns with long-term potentiation. Consult your provider — this compound is in very early research stages.
NOT FDA-approved. Research chemical status. No clinical trials registered for human use as of 2025. Significant caution warranted.